

Towards the Industrialisation of Stem Cell-Derived Therapies

Dr Jahid Hasan

The Industrialisation Team



70

Team of dedicated scientists

Made up of process engineers, cell biologist, analytical scientists, immunologists, data scientists

25

Average number of new project commencing each year Typical project duration of 1 - 3 years

Collaboration


The team has worked on projects with large pharma,

SME's, leading academic groups and technology developers



PSC Potential






npj Regenerative Medicine (2020) 5:15 ; https://doi.org/10.1038/s41536-020-00100-4




Indication	Therapeutic cell type	Annual incidence in UK	Predicted cell/dose	Annual cell requirement
Type I diabetes	Pancreatic b-cells	15,000	2 x10 ⁶ /kg	2.4 x10 ¹²
Macular degeneration	Retinal epithelial	20,000	0.5-2 x10 ⁵	2 x10 ⁹
Osteoarthritis	MSC/Chondrocytes	20,000	2 x10 ⁶ /kg	3.2 x10 ¹²
Liver Failure	Hepatocytes	12,000	1 x10 ⁸	1.2 x10 ¹²

Current production paradigm








10 ¹² cells per year				
@ 2 x10 ⁵ cells/cm ²	=	1200 CF10		





Adherent PSC expansion






Automated	vs. Manual
Labour	↓ 67%
CoGs	↓ 40%
Capex	↑ 9%
Throughput	↑ 250%

TERUMOBCT


Surface area = $2.1 \text{ m}^2 = -4x \text{ CF10}$



10 ¹² cells per year					
@ 2 x10 ⁵ cells/cm ²	= 300 Quantum's				


Assure product manufacture






Suspension PSC expansion: Scale Up






Closing the process from start to finish





Perfusion: increased yield and quality





Automated buffer exchange





Method

- Fluidised bed centrifugation (kSep[®])
- Spinning membrane filtration (LoVo[®])

Cell separation technologies

- For removal of passaging agent
- For change to differentiation medium
- For before and after selection, transduction, etc.







LoVo®





DoE as a differentiation optimisation tool




Methodology developed to optimise differentiation processes to in-house iPSC bank

Identification of universally scalable metric


Potential to use as GMP cell line screening tool

Increased process understanding can be applied to achieve CoGs reduction




2D Confluency assay – Online WebApp






Analytical capabilities





PAT: Raman as example





Stem Cell Expansion and Differentiation Team

Moira

Carolina

Rob







Matthew







Jahid





Mallika



John





Esther

Sam

Marcia



Mudith

Oliver



Iris

Juan

Chris





Natacha



Elena













Marianne



CATAPULT Cell and Gene Therapy

Cell and Gene Therapy Catapult is committed to ensuring high standards of research integrity and research best practice in the activities we carry out. We subscribe to the principles described in the UK concordat to support research integrity.

Cell and Gene Therapy Catapult is a trading name of Cell Therapy Catapult Limited, registered in England and Wales under company number 07964711, with registered office at 12th Floor Tower Wing, Guy's Hospital, Great Maze Pond, London, SE1 9RT. VAT number 154 4214 33.

12th Floor Tower Wing Guy's Hospital Great Maze Pond London SE1 9RT

info@ct.catapult.org.uk ct.catapult.org.uk Twitter: @CGTCatapult



Innovate UK